DE60017446D1 - Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität - Google Patents
Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivitätInfo
- Publication number
- DE60017446D1 DE60017446D1 DE60017446T DE60017446T DE60017446D1 DE 60017446 D1 DE60017446 D1 DE 60017446D1 DE 60017446 T DE60017446 T DE 60017446T DE 60017446 T DE60017446 T DE 60017446T DE 60017446 D1 DE60017446 D1 DE 60017446D1
- Authority
- DE
- Germany
- Prior art keywords
- 5ht1b
- isochinoline
- 5ht1a
- combined
- receptor activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title abstract 4
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 title 1
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 title 1
- 101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9926304 | 1999-11-05 | ||
| GBGB9926304.8A GB9926304D0 (en) | 1999-11-05 | 1999-11-05 | Novel compounds |
| GB0017880 | 2000-07-20 | ||
| GB0017880A GB0017880D0 (en) | 2000-07-20 | 2000-07-20 | Novel compounds |
| PCT/EP2000/010908 WO2001032626A1 (en) | 1999-11-05 | 2000-11-02 | Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60017446D1 true DE60017446D1 (de) | 2005-02-17 |
| DE60017446T2 DE60017446T2 (de) | 2006-03-02 |
Family
ID=26244692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60017446T Expired - Fee Related DE60017446T2 (de) | 1999-11-05 | 2000-11-02 | Isochinolin- und Chinazolinderivate mit kombinierter 5-HT1A-, 5-HT1B- und 5-HT1D- Rezeptoraffinität |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050239797A1 (de) |
| EP (1) | EP1228043B1 (de) |
| JP (1) | JP2003513075A (de) |
| AT (1) | ATE286883T1 (de) |
| AU (1) | AU1028601A (de) |
| DE (1) | DE60017446T2 (de) |
| ES (1) | ES2234683T3 (de) |
| PE (1) | PE20010956A1 (de) |
| UY (1) | UY26426A1 (de) |
| WO (1) | WO2001032626A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2408913A1 (en) | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
| DE10315571A1 (de) * | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Pyrazolverbindungen |
| DE10315573A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Substituierte Pyrazole |
| DE10315569A1 (de) * | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Substituierte Pyrazolverbindungen |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| WO2005012256A1 (en) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| JP4533391B2 (ja) * | 2004-01-16 | 2010-09-01 | エフ．ホフマン−ラ ロシュ アーゲー | 中枢神経系疾患の処置のための５−ヒドロキシトリプタミンレセプター（５−ｈｔ）のモジュレーターとしての、１−ベンジル−５−ピペラジン−１−イル−３，４−ジヒドロ−１ｈ−キナゾリン−２−オン誘導体、ならびにそれぞれの１ｈ−ベンゾ（１，２，６）チアジアジン−２，２−ジオキシドおよび１，４−ジヒドロベンゾ（ｄ）（１，３）オキサジン−２−オン誘導体 |
| US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| US20090099175A1 (en) * | 2006-03-01 | 2009-04-16 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| EP2139481B1 (de) | 2007-03-21 | 2013-08-21 | The University Of Montana | 1-[(2'-substituierte)-piperazin-1'-yl]-isochinoline als norepinephrin-transporthemmende therapeutika und mittel zur abbildung einer positronenemissionstomographie |
| WO2012102405A1 (ja) | 2011-01-28 | 2012-08-02 | 佐藤製薬株式会社 | 縮環化合物 |
| US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
| KR101709127B1 (ko) * | 2015-06-16 | 2017-02-22 | 경동제약 주식회사 | Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법 |
| CN112480007B (zh) * | 2020-12-08 | 2022-11-18 | 宿迁市科莱博生物化学有限公司 | 一种1，3-二甲基-1h-吡唑-4-羧酸的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3778440A (en) * | 1970-12-07 | 1973-12-11 | Sandoz Ag | 1-substituted amino-isoquinolines and nitrates thereof |
| US3932412A (en) * | 1970-12-07 | 1976-01-13 | Sandoz, Inc. | 1-(4-Hydroxyalkylpiperazino)-isoquinoline nitrates |
| IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| WO1998047868A1 (en) * | 1997-04-18 | 1998-10-29 | Smithkline Beecham Plc | Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists |
| CA2288662A1 (en) * | 1997-04-18 | 1998-11-12 | Smithkline Beecham P.L.C. | Indole derivatives having combined 5ht1a, 5ht1b and 5ht1d receptor antagonist activity |
| WO1999018077A1 (fr) * | 1997-10-02 | 1999-04-15 | Eisai Co., Ltd. | Derives de pyridine condenses |
| CA2313125A1 (en) * | 1997-12-12 | 1999-06-24 | Laramie Mary Gaster | Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists |
| WO2000006575A2 (en) * | 1998-07-28 | 2000-02-10 | Smithkline Beecham Plc | Azabicyclic compounds |
-
2000
- 2000-11-02 DE DE60017446T patent/DE60017446T2/de not_active Expired - Fee Related
- 2000-11-02 EP EP00971423A patent/EP1228043B1/de not_active Expired - Lifetime
- 2000-11-02 ES ES00971423T patent/ES2234683T3/es not_active Expired - Lifetime
- 2000-11-02 AU AU10286/01A patent/AU1028601A/en not_active Abandoned
- 2000-11-02 AT AT00971423T patent/ATE286883T1/de not_active IP Right Cessation
- 2000-11-02 WO PCT/EP2000/010908 patent/WO2001032626A1/en active IP Right Grant
- 2000-11-02 JP JP2001534778A patent/JP2003513075A/ja active Pending
- 2000-11-03 UY UY26426A patent/UY26426A1/es not_active Application Discontinuation
- 2000-11-03 PE PE2000001176A patent/PE20010956A1/es not_active Application Discontinuation
-
2005
- 2005-06-13 US US11/151,008 patent/US20050239797A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2234683T3 (es) | 2005-07-01 |
| WO2001032626A1 (en) | 2001-05-10 |
| ATE286883T1 (de) | 2005-01-15 |
| AU1028601A (en) | 2001-05-14 |
| US20050239797A1 (en) | 2005-10-27 |
| JP2003513075A (ja) | 2003-04-08 |
| PE20010956A1 (es) | 2001-09-15 |
| DE60017446T2 (de) | 2006-03-02 |
| EP1228043B1 (de) | 2005-01-12 |
| UY26426A1 (es) | 2001-05-31 |
| EP1228043A1 (de) | 2002-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60203797D1 (de) | Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten | |
| DE60017446D1 (de) | Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität | |
| TR200101859T2 (tr) | Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler | |
| WO2004058717A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| EE200200217A (et) | Asendatud indoolid NFkB aktiivsuse moduleerimiseks, nende valmistamismeetod ja kasutamine ning ravim ja selle valmistamismeetod | |
| MY132229A (en) | Indole derivatives as 5-ht receptor antagonist | |
| MY119181A (en) | Aryl pyrimidine derivatives | |
| ATE302606T1 (de) | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren | |
| CY1106165T1 (el) | Παραγωγα ινδολινονης για την τροποποιηση της c-kit πρωτεϊνικης τυροσινικης κινασης | |
| DK1194425T3 (da) | Substituerede benzimidazoler | |
| NO20034122D0 (no) | Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte | |
| ATE288747T1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
| ATE275400T1 (de) | Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ | |
| ATE346068T1 (de) | Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden | |
| ZA200107143B (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders. | |
| PT1000046E (pt) | Derivados de piperazina activos no trato urinario inferior | |
| DE60140530D1 (de) | 5-ht7 rezeptor-antagonisten | |
| DK1626973T3 (da) | (1S,5S)-3-(5,6-dichlor-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptan med analgesisk virkning | |
| DE60015187D1 (de) | Urotensin-ii rezeptorantagonisten | |
| BG105984A (bg) | Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението | |
| BR9907170A (pt) | Composições farmacêuticas e métodos para uso | |
| SE9901079D0 (sv) | Novel compounds | |
| TR200000916T2 (tr) | İkameli piperidin türevleri. | |
| SE9802207D0 (sv) | Novel compounds | |
| ECSP003751A (es) | Nuevos compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |